top of page
Search

Psychedelics developer secures $100 million to support the final phase of its application for regulatory approval to sell Ecstasy for PTSD

MAPS has launched the only psychedelic-assisted therapy research program that has completed two successful Phase 3 studies and submitted a New Drug Application to the FDA.


A decade after being founded as a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has secured more than $100 million in a Series A private stock sale. The fund will support the final phase of its application for regulatory approval to sell MDMA, also known as Ecstasy, as a treatment for post-traumatic stress disorder (PTSD).

MAPS has launched the only psychedelic-assisted therapy research program that has completed two successful Phase 3 studies and submitted a New Drug Application to the FDA.


In addition to the Series A financing, led by Helena – a hedge-fund manager-funded foundation joe samberg – The organization will change its name to Lycos Therapeutics.


“We are extremely grateful to partner with Protik Basu and the rest of the Helena team of mission-aligned investors who understand our priority of public benefit and care deeply about humanitarian causes.”


Rick Doblin, Ph.D. the founder and president of MAPS said in a company press release Friday. “Together, we can uphold our commitment to the trial participants, physicians, scientists, other partners and collaborators, and donors who have devoted nearly four decades to researching innovative investigational treatments for PTSD for the public benefit. “Dedicated myself to.”


Source: Multidisciplinary Association for Psychedelic Studies


_______________________________________________________

What are your company's business or financial objectives?









If your company has business or financial objectives, check out the advisory services for growing global technology companies provided by FC Global Strategies.


In addition to Medical and Pharma Insider, FC Global Strategies also sponsors Emerging Technology Insider.


Our calendar link to schedule a complementary call.


FC Global Strategies' Regional Directors:


Jeffrey Friedland - Based in the U.S.

(North America and Global)

+1 646 450 8909


Ross Swan - Based in Singapore

(Southeast Asia, Australia, Asia-Pacific)

+65 9181 9472


David Krutonog - Based in Israel

(Eastern Europe, Middle-East and North Africa

+972 50 974 3429


Claudio Hebling - Based in Brazil

(Latin America)

+55 19 99377 748


Vincent Paul Joseph - Based in India

(South Asia, India and Sri Lanka)

+91 962 620 9090


Olah Abiodun - Based in Nigeria

(Africa)

+234 812 029 8222







bottom of page